Cargando…
Prognostic factors in conversion surgery following nab‐paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual‐center study
BACKGROUND: In pancreatic ductal adenocarcinoma (PDAC), only radical surgery improves long‐term survival. We focused on surgical outcome after induction gemcitabine along with nab‐paclitaxel (GnP) and subsequent chemoradiotherapy (CRT) with S‐1 administration for unresectable locally advanced (UR‐LA...
Autores principales: | Igarashi, Takamichi, Yamada, Suguru, Hoshino, Yui, Murotani, Kenta, Baba, Hayato, Takami, Hideki, Yoshioka, Isaku, Shibuya, Kazuto, Kodera, Yasuhiro, Fujii, Tsutomu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831906/ https://www.ncbi.nlm.nih.gov/pubmed/36643365 http://dx.doi.org/10.1002/ags3.12613 |
Ejemplares similares
-
The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
por: Takada, Ryoji, et al.
Publicado: (2021) -
Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer
por: Kimura, Nana, et al.
Publicado: (2020) -
Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study
por: Takano, Nao, et al.
Publicado: (2019) -
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022) -
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Shirakawa, Tsuyoshi, et al.
Publicado: (2023)